Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities

Executive Summary

US FDA commissioner says primary use of proposed budget boost would be border security; budget documents state that special opioid epidemic funding also would support regulatory science and diagnostic development.

You may also be interested in...



FDA Joins Forces With Customs Office To Beef Up Scrutiny of Drug Packages At Borders

The US FDA and the US customs office have agreed to team up and establish an expanded scientific presence at International Mail Facility locations deemed “high risk” ports of entry to deter illegal opioids and counterfeit drugs from entering US borders.

Opioid Approvals: Congress Wants US FDA Guidance On Abuse Potential

Instead of creating new mandate, legislation tells FDA to outline how risk-benefit decisions could be influenced by a product's abuse potential under existing approval authority; final opioids package expected to reach the White House soon.

US House Committee Requests Proof Of FDA Progress Seizing Opioids In International Mail

Energy & Commerce's Republican and Democrat leadership ask FDA Commissioner Scott Gottlieb about work by the agency's Office of Criminal Investigations focused on opioid drugs, the office's staffing and its priorities. They note FDA's FY2018 appropriation included $94m for its work in international mail facilities.

Related Content

Topics

UsernamePublicRestriction

Register

PS122565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel